Precigen Inc (OQ:PGEN)

Business Focus: Pharmaceuticals

Apr 24, 2024 10:20 am ET

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASC

GERMANTOWN, Md., April 24, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy for the treatment of patients with recurrent respiratory papillomatosis (RRP) will be presented in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4, 2024 at McCormick Place in Chicago, Illinois.

Apr 24, 2024 09:00 am ET

Actym Therapeutics Appoints Thomas Smart as CEO

BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later thi

Mar 28, 2024 04:05 pm ET

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials –

Feb 06, 2024 03:05 pm ET

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GERMANTOWN, Md., Feb. 6, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13 to February 14, 2024. Precigen's company presentation will take place on Tuesday, February 13 from 3:20 PM to 3:50 PM EST.

Jan 16, 2024 07:05 am ET

Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

– Designation is an important step toward bringing this potentially life-changing therapy to European patients –

Jan 08, 2024 07:30 am ET

Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

– PRGN-2012 Phase 2 pivotal study data in RRP is anticipated in the second quarter of 2024; the Company plans to submit a BLA under an accelerated approval pathway in the second half of 2024; commercial readiness preparations are underway for a potential launch in 2025 –

Dec 18, 2023 03:05 pm ET

Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 PM PT/8:15 PM ET in San Francisco, California.

Nov 29, 2023 03:05 pm ET

Precigen to Participate in the JMP Securities Hematology and Oncology Summit

GERMANTOWN, Md., Nov. 29, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 3:00 PM ET.

Nov 09, 2023 03:55 pm ET

Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

– Based on FDA confirmation in August 2023 that the ongoing Phase 1/2 single-arm study of PRGN-2012 in RRP will serve as the pivotal study to support BLA submission under an accelerated approval request, the Company has expedited efforts to attain commercial readiness –

Nov 07, 2023 03:05 pm ET

Precigen to Participate in the Stifel 2023 Healthcare Conference

GERMANTOWN, Md., Nov. 7, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a company overview at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 10:55 AM ET in New York.

Sep 19, 2023 04:05 pm ET

Precigen to Participate in Upcoming Leading Investor and Industry Conferences

GERMANTOWN, Md., Sept. 19, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the following upcoming investor and industry conferences:

Aug 09, 2023 06:14 pm ET

Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against each of these companies. To receive a pro-rata share of the settlement proceeds, members of the class must...

Jun 20, 2023 09:31 am ET

Thinking about buying stock in Cano Health, Dragonfly Energy Holdings, Lordstown Motors, Precigen, or Applied Optoelectronics?

NEW YORK, June 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANO, DFLI, RIDE, PGEN, and AAOI.

Jun 20, 2023 07:30 am ET

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

– First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP –– Designation based on positive Phase 1 clinical data that showed 50% of patients were "surgery-free" (Complete Response) after PRGN-2012 treatment with a minimum follow up of 12 months post-treatment –

Jun 05, 2023 04:05 pm ET

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity –– PRGN-3005 cells demonstrated expansion and persistence when delivered via either intraperitoneal or intravenous infusion without lymphodepletion or via intravenous infusion after lymphodepletion demonstrating the effectiveness of mbIL15 –– A single intravenous infusion following lymphodepletion decreased tumor burden in 67% of the heavily pretreated patients (median of 8 or more prior therapies) with 90% of individual target lesions showing stable disease or partial response

Jun 03, 2023 12:00 pm ET

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastat

– PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses –

May 31, 2023 08:05 am ET

Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Ce

– HPV is responsible for more than 90 percent of cervical cancer cases globally with approximately 300,000 women living with cervical cancer in the US –

May 10, 2023 08:00 am ET

Precigen Reports First Quarter 2023 Financial Results and Business Updates

– Positive Phase 1 clinical data presented for PRGN-2012 AdenoVerse™ immunotherapy in RRP demonstrated favorable safety profile and significant reduction in surgeries with 50% of the patients in Complete Response following treatment with PRGN-2012 –

May 03, 2023 08:30 am ET

Precigen to Announce First Quarter 2023 Financial Results on May 10th

GERMANTOWN, Md., May 3, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release first quarter 2023 financial results on Wednesday, May 10, 2023. The Company will host a conference call that day at 8:00 AM ET to discuss financial results and provide a general business update.

Apr 26, 2023 04:05 pm ET

Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting

GERMANTOWN, Md., April 26, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the Phase 1 dose escalation study of PRGN-3005 UltraCAR-T in patients with advanced, recurrent platinum resistant ovarian cancer, and the Phase I study of PRGN-2009 AdenoVerse immunotherapy alone or in combination with an anti-PDL1/TGF-Beta trap checkpoint inhibitor in patients with HPV-associated cancers will be presented at the 2023 American Societ

Apr 17, 2023 09:01 am ET

Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023

– First preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR) –

Apr 03, 2023 04:30 pm ET

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

– Precigen amends exclusive license agreement with Alaunos to bolster portfolio and broaden strategic opportunities –– The Company also regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform– Agreement eliminates all future royalties to Alaunos –– Precigen to host business and clinical update call on Tuesday, April 4, 2023 at 8:30 AM ET –

Mar 29, 2023 08:05 am ET

Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors

– Milestone represents the first patient dosed with the next generation UltraCAR-T, incorporating PD-1 checkpoint inhibition in addition to three effector genes –– Proprietary technology for checkpoint blockade intrinsic to UltraCAR-T cells avoids the need for combination with a systemic checkpoint inhibitor, potentially limiting cost and systemic toxicity –

Mar 28, 2023 08:05 am ET

Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium

GERMANTOWN, Md., March 28, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat on April 4, 2023 from 10:45 AM to 11:15 AM ET at Cantor's "The Future of Oncology" Virtual Symposium.

Jan 27, 2023 03:05 pm ET

Precigen Announces Closing of Public Offering of Common Stock

GERMANTOWN, Md., Jan. 27, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Gross proceeds to Precigen from the offering were approximately $75.0 million before deducting the underwriting discount and other offering expenses payable by Precigen.

Jan 24, 2023 09:40 pm ET

Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock

GERMANTOWN, Md., Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 6,428,571 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75.0 million, excluding any exercise of the underwriters' option. The offering is ex

Jan 24, 2023 03:05 pm ET

Precigen Announces Proposed $75.0 Million Public Offering of Common Stock

GERMANTOWN, Md., Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. All of the shares in the proposed offering are to be sold by Precigen.

Jan 24, 2023 03:01 pm ET

Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosi

– Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 –

Jan 11, 2023 05:45 pm ET

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

– Company achieved significant progress for its clinical pipeline in 2022 –– Precigen to host R&D Day virtual event on January 24, 2023, at 4:30 PM ET to share safety and efficacy data from the Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse™ immunotherapy in recurrent respiratory papillomatosis (RRP) –

Jan 04, 2023 03:05 pm ET

Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respir

GERMANTOWN, Md., Jan. 4, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host an investigator-led R&D event on January 24, 2023 at 4:30 PM ET to showcase the latest clinical advancements for the Company's investigational, first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ Immunotherapy in recurrent respiratory papillomatosis (RRP).

Dec 19, 2022 03:05 pm ET

Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PT/6:45 PM ET in San Francisco, California.

Dec 12, 2022 06:01 pm ET

Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow –

Nov 09, 2022 03:05 pm ET

Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs

– Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete clinical trial data from Phase 1 dose escalation and expansion cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in recurrent respiratory papillomatosis (RRP) –

Nov 02, 2022 04:30 pm ET

Precigen to Announce Third Quarter 2022 Financial Results on November 9th

GERMANTOWN, Md., Nov. 2, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release third quarter 2022 financial results after the market closes on Wednesday, November 9, 2022. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

Sep 21, 2022 04:30 pm ET

Precigen Names Rutul R. Shah Chief Operating Officer

GERMANTOWN, Md., Sept. 21, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Rutul R. Shah as the Company's Chief Operating Officer (COO), effective October 1, 2022. Mr. Shah has been with the Company since 2014 and has served in roles of increasing responsibility throughout his tenure, most recently as Head of Operations and Portfolio. In this newly created COO role, Mr. Shah will have responsibility for strategic management of the Company's port

Sep 01, 2022 08:05 am ET

Precigen to Participate in the 2022 Wells Fargo Healthcare Conference

GERMANTOWN, Md., Sept. 1, 2022 /PRNewswire/ -- Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference in Boston, Massachusetts on Wednesday, September 7, 2022 at 11:35 AM ET.

Aug 22, 2022 08:05 am ET

Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

– Proceeds include $170 million in upfront cash and up to $10 million earn-out over two years –

Aug 08, 2022 04:05 pm ET

Precigen Reports Second Quarter and First Half 2022 Financial Results

– Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo Clinic in Rochester, Minnesota activated as first expansion site of Phase 1b multicenter expansion; technology transfer and site activation activities underway at multiple new sites –

Aug 01, 2022 04:05 pm ET

Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th

GERMANTOWN, Md., Aug. 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2022 financial results after the market closes on Monday, August 8, 2022. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

Jun 27, 2022 04:05 pm ET

Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit

GERMANTOWN, Md., June 27, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual panel discussion titled, "Targeted T Cell Therapies, Including Autologous CAR T, TCR and More" on Thursday, June 30, 2022, at 1:00 PM ET at the Stifel 2022 Virtual Cell Therapy Summit.

May 17, 2022 04:05 pm ET

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

GERMANTOWN, Md., May 17, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the 2022 H.C. Wainwright Global Investment Conference. A webcast of the event will be available beginning at 7:00 AM ET on Tuesday, May 24, 2022.

May 09, 2022 04:05 pm ET

Precigen Reports First Quarter 2022 Financial Results and Business Updates

– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing disease with limited treatment options –

Apr 04, 2022 08:05 am ET

Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

– Acute myeloid leukemia (AML) is among the most common types of leukemia in adults –

Mar 28, 2022 09:00 pm ET

PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON) on behalf of long-term stockholders following a class action complaint that was filed against Precigen on October 5, 2020 with a Class Period from May 10, 2017 to September 25, 2020. Our investigation concerns whether the board of directors of Precigen have breached their fiduciary duties to the company.

Mar 01, 2022 07:00 am ET

Precigen Reports Fourth Quarter and Full Year 2021 Financial Results

GERMANTOWN, Md., March 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results.

Jan 12, 2022 03:30 pm ET

Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Jan. 12, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 40th Annual J.P. Morgan Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2021 achievements and set forth Precigen's goals for 2022.

Jan 05, 2022 03:05 pm ET

Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Jan. 5, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 PM ET.

Dec 13, 2021 04:05 pm ET

Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

GERMANTOWN, Md., Dec. 13, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive interim data at the 63rd ASH Annual Meeting and Exposition (Abstract# 825) from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261). The oral presentation was delivered by David Sallman, MD, Assistant Me

Nov 10, 2021 03:05 pm ET

Precigen to Present at the Stifel 2021 Virtual Healthcare Conference

GERMANTOWN, Md., Nov. 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in the Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021 at 10:40 AM ET.

Nov 04, 2021 09:15 am ET

Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies

GERMANTOWN, Md., Nov. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced a topline summary of the presentations planned for today's 2021 R&D Day virtual event, which begins at 11:00 AM ET. Participants may register and access the live webcast through Precigen's investor relations website in the Events & Presentations section.

Oct 27, 2021 04:38 pm ET

Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments

GERMANTOWN, Md., Oct. 27, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a virtual event on Thursday, November 4, 2021 at 11:00 AM ET to provide an update on the progress for its clinical pipeline.

Oct 26, 2021 08:05 am ET

Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors

GERMANTOWN, Md., Oct. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate the Phase 1/1b clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors. PRGN-3007 is a first-in-class investigational therapy based on the next generation of Precigen's Ultra

Oct 12, 2021 08:05 am ET

Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer

GERMANTOWN, Md., Oct. 12, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Harry Thomasian Jr. as the Company's chief financial officer (CFO), effective October 18, 2021. Mr. Thomasian will oversee the Company's corporate financial strategy and planning, and provide a critically important strategic perspective to business development, licensing, and corporate financing initiatives. Mr. Thomasian will report to Precigen's Pre

Oct 01, 2021 08:05 am ET

Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

GERMANTOWN, Md., Oct. 1, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24). Results were presented in an oral presentation entitled, "AG019 ActoBiotics as monotherapy or in a

Sep 01, 2021 08:05 am ET

Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference

GERMANTOWN, Md., Sept. 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in two upcoming conferences. Dr. Sabzevari will participate in a virtual fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference on Thursday, September 9, 2021 at 8:40 AM ET, and present at the H.C. Wainwright 23rd Annual Global Investment Conference. The H.C. Wainwright webcast will be av

Aug 09, 2021 04:01 pm ET

Precigen Reports Second Quarter and First Half 2021 Financial Results

GERMANTOWN, Md., Aug. 9, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2021 financial results.

Aug 02, 2021 04:05 pm ET

Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th

GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial results after the market closes on Monday, August 9, 2021. The Company will host a conference call that day at 4:05 PM ET to discuss financial results and provide a general business update.

Jun 11, 2021 08:30 am ET

Thinking about buying stock in Novan, Chemomab Therapeutics, Precigen, ChemoCentryx, or Senseonics?

NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, CMMB, PGEN, CCXI, and SENS.

Jun 10, 2021 05:05 pm ET

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

GERMANTOWN, Md., June 10, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced positive topline results for the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24). Results from the primary analysis were presented at the Federation of Clinical Immunology Societies (FOCIS) 2021 Virtual

Jun 10, 2021 04:05 pm ET

Precigen to Present at the JMP Securities Life Sciences Conference

GERMANTOWN, Md,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat at the annual JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 11:00 AM ET.

Feb 22, 2021 03:05 pm ET

Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st

GERMANTOWN, Md., Feb. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release fourth quarter and full year 2020 financial results after the market closes on Monday, March 1, 2021. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

Feb 04, 2021 03:05 pm ET

Precigen to Participate in Guggenheim Healthcare Talks Oncology Day

GERMANTOWN, Md., Feb. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day on Friday, February 12, 2021 at 11:30 AM ET.

Jan 26, 2021 03:05 pm ET

Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

GERMANTOWN, Md., Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public offering price of $7.50 per share, including the exercise in full by the underwriters of their option to purchase an additional 2,250,000 shares of common stock. Gross proceeds to Precigen from the offering were approximately $129.4 million before deducting the underwriting discount and other offering expenses payable by Precigen.

Jan 22, 2021 07:05 am ET

Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock

GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option. The offering is e

Jan 21, 2021 03:01 pm ET

Precigen Announces Proposed Public Offering of Common Stock

GERMANTOWN, Md., Jan. 21, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of shares of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering.

Jan 13, 2021 03:05 pm ET

Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Jan. 13, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented clinical and preclinical updates at the 39th Annual J.P. Morgan Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2020 clinical achievements and set forth Precigen's clinical goals for 2021.

Jan 06, 2021 07:05 am ET

Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Jan. 6, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 3:40 PM ET.

Jan 05, 2021 07:05 am ET

Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

GERMANTOWN, Md., Jan. 5, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I clinical trial of Precigen's PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP). RRP is a rare, difficult-to-treat and sometimes fatal neop

Dec 15, 2020 06:37 pm ET

Precigen Provides Latest Clinical Developments at Virtual R&D Update Event

GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today held an R&D virtual event to provide an update on the latest progress for its clinical pipeline.

Dec 08, 2020 03:05 pm ET

Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments

GERMANTOWN, Md., Dec. 8, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a virtual event on Tuesday, December 15, 2020 at 11:00 AM ET to provide an update on the latest progress for its clinical pipeline.

Dec 07, 2020 09:05 am ET

Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition

GERMANTOWN, Md., Dec. 7, 2020 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced at the 62nd ASH Annual Meeting and Exposition (Abstract 2864) clinical progress and new data from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) (clinical trial identifier: NCT03927261).

Dec 04, 2020 11:00 am ET

PGEN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Notifies Precigen, Inc. f/k/a Intrexon Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 4, 2020

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Precigen, Inc. f/k/a Intrexon Corporation (“Precigen” or the "Company") (NASDAQ: PGEN) (NASDAQ: XON) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Precigen securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:

Dec 04, 2020 08:00 am ET

Precigen Inc. f/k/a/ Intrexon Corporation: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Precigen Inc. f/k/a/ Intrexon Corporation (NASDAQ: PGEN) investors that acquired shares between May 10, 2017 and September 25, 2020. Investors have until...

Dec 03, 2020 04:53 pm ET

PGEN DEADLINE TOMORROW: Hagens Berman, National Trial Attorneys, Alerts Precigen, Inc. (PGEN) Investors to Application Deadline, Encourages Investors with Losses to Contact Its Attorneys

Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead...

Dec 03, 2020 01:19 pm ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Precigen, Inc. f/k/a Intrexon Corporation (“Precigen” or the “Company”) (NASDAQ: PGEN). The class action, filed in United States District Court for the...

Dec 03, 2020 10:40 am ET

Zhang Investor Law Alerts Investors to December 4 Deadline in Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation – PGEN, XON

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the “Class Period”). To join...

Dec 03, 2020 03:25 am ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline - PGEN

NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Precigen, Inc. f/k/a Intrexon Corporation ("Precigen" or the "Company") (NASDAQ: PGEN). The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-07442, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired the Company's securities between May 10, 2017 and March 2, 2020, both dates inclusive (the "Class Period"). Plaintiff seeks to recover c

Dec 02, 2020 11:00 am ET

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Precigen, Inc. (“Precigen” or the “Company”) f/k/a Intrexon...

Dec 01, 2020 10:59 pm ET

ROSEN, TOP RANKED AND TRUSTED INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Fir

NEW YORK, Dec. 1, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors under the federal securities laws.

Dec 01, 2020 01:42 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Precigen, Inc. (PGEN) Investors to December 4th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact Its Attorneys

SAN FRANCISCO, Dec. 1, 2020 /PRNewswire/ -- Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff.

Dec 01, 2020 11:00 am ET

PGEN, MESO & LOOP Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Nov 30, 2020 08:00 pm ET

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Precigen, Inc. f/k/a Intrexon Corporation and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that...

Nov 30, 2020 11:00 am ET

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

Nov 28, 2020 01:16 pm ET

PGEN 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Precigen, Inc. (PGEN) Investors with Losses to Contact Its Attorneys, Securities Fraud Deadline Approaching

Nov 27, 2020 05:00 pm ET

UPCOMING DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon-- PGEN, XON

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Precigen, Inc. f/k/a (NASDAQ: PGEN, XON) from May 10, 2017 through September 25, 2020, inclusive (the “Class Period”). The...

Nov 27, 2020 09:11 am ET

PGEN INVESTOR DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

NEW YORK, Nov. 27, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors that purchased or acquired the securities of Precigen Inc. ("Precigen" or the "Company") (NASDAQ: PGEN) (NASDAQ: XON) between May 10, 2017 and September 25, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

Nov 25, 2020 12:52 pm ET

Scott+Scott Attorneys at Law LLP Alerts Investors to December 4 Lead Plaintiff Deadline in Securities Class Actions Against Precigen, Inc. (PGEN)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors that class action lawsuits are pending against Precigen, Inc. (“Precigen” or the “Company”) (NASDAQ: PGEN) (formerly Intrexon Corp. (NYSE: XON)) and ce

Nov 25, 2020 11:00 am ET

PGEN, MESO & LOOP Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm

Nov 24, 2020 06:00 pm ET

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Precigen, Inc. f/k/a Intrexon Corporation and Encourages Investors to Contact the Firm

Nov 24, 2020 11:00 am ET

DEADLINE ALERT for TCMD, CACC, ACB, PGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Nov 24, 2020 10:18 am ET

PGEN LOOMING DEADLINE: Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation – PGEN, XON

Nov 24, 2020 09:16 am ET

PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors that purchased or acquired the...

Nov 23, 2020 03:12 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates LOOP, PGEN, TILE Investors on Approaching Securities Fraud Deadlines, Encourages Investors with Losses to Contact the Firm

Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases, including important upcoming deadlines, can be found at the...

Nov 23, 2020 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Precigen, Inc. (“Precigen” or the...

Nov 22, 2020 12:23 am ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

Nov 20, 2020 05:41 pm ET

ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourage

Nov 19, 2020 10:58 am ET

PGEN, XON IMPORTANT DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon-- PGEN, XON

Nov 18, 2020 05:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop Industries and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN; XON), Royal Caribbean...

Nov 17, 2020 05:05 pm ET

PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

Nov 17, 2020 12:30 pm ET

DEADLINE ALERT for TCMD, CACC, ACB, PGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Nov 17, 2020 09:39 am ET

PGEN IMMINENT DEADLINE: Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation – PGEN, XON

Nov 16, 2020 09:50 pm ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

Nov 16, 2020 04:49 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, Securities Fraud Action Filed, Important Deadline

Nov 16, 2020 11:30 am ET

DEADLINE ALERT for CACC, ACB, and PGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

Nov 16, 2020 07:05 am ET

Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured Using Proprietary UltraPorator™ System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials

GERMANTOWN, Md., Nov. 16, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical implementation of its UltraPorator™ system, a device exclusive to Precigen for the scale-up of rapid and cost-effective decentralized manufacturing of UltraCAR-T® therapies. Precigen and its clinical partners have now successfully dosed the first patients with UltraCAR-T cells manufactured using the UltraPorator system. The patients were dosed with PRGN-3005 Ul

Nov 13, 2020 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

Nov 12, 2020 07:05 pm ET

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages In

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors under the federal securities laws.

Nov 12, 2020 03:21 pm ET

SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon- PGEN, XON; IMPORTANT DEADLINE –Precigen, Inc. f/k/a Intrexon Corporation– PGEN,

Nov 12, 2020 08:47 am ET

PGEN INVESTOR DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors that purchased or acquired the securities of Precigen Inc. ("Precigen" or the "Company") (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

Nov 12, 2020 08:00 am ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

Nov 11, 2020 05:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Credit Acceptance Corporation, Precigen, Royal Caribbean, and Mesoblast and Encourages Investors to Con

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Credit Acceptance Corporation (NASDAQ: CACC), Precigen, Inc. f/k/a Intrexon...

Nov 11, 2020 01:25 pm ET

PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

Nov 11, 2020 11:00 am ET

ACB & PGEN Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

Nov 10, 2020 11:00 am ET

DEADLINE ALERT for CACC and PGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Nov 09, 2020 04:07 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, Securities Fraud Action Filed, Important Deadline

Nov 09, 2020 12:00 pm ET

DEADLINE ALERT for TCMD, CACC, ACB, PGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Nov 09, 2020 07:05 am ET

Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results

GERMANTOWN, Md., Nov. 9, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter and year-to-date financial results for 2020.

Nov 08, 2020 03:03 am ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

Nov 06, 2020 07:22 pm ET

ROSEN, A LEADING LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investo

Nov 06, 2020 04:28 pm ET

PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

Nov 06, 2020 11:30 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

Nov 04, 2020 06:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop Industries and Encourages Investors to Contact the Firm

Nov 04, 2020 11:00 am ET

DEADLINE ALERT for CACC, ACB, and PGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Nov 03, 2020 12:57 pm ET

Moore Kuehn, PLLC Encourages Investors of CLSN, PGEN or TCMD to Contact Law Firm

Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false...

Nov 02, 2020 10:22 pm ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

Nov 02, 2020 03:05 pm ET

Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early December

GERMANTOWN, Md., Nov. 2, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release third quarter 2020 financial results on Monday, November 9th, 2020. The Company plans to host a call in early December to provide an update on the progress of its clinical pipeline.

Nov 02, 2020 01:33 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates LOOP, PGEN, TCMD Investors on Securities Fraud Actions, Encourages Investors with Losses to Contact the Firm

Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. LOOP Investors Click Here....

Nov 02, 2020 12:00 pm ET

DEADLINE ALERT for TCMD, CACC, ACB, PGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Oct 30, 2020 04:58 pm ET

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm– PGEN,

Oct 30, 2020 11:18 am ET

PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

Oct 29, 2020 07:05 pm ET

ROSEN, A LEADING LAW FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important December 4 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investo

NEW YORK, Oct. 29, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors under the federal securities laws.

Oct 29, 2020 12:00 pm ET

DEADLINE ALERT for CACC, ACB, and PGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Oct 29, 2020 11:17 am ET

PGEN INVESTOR DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

NEW YORK, Oct. 29, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors that purchased or acquired the securities of Precigen Inc. ("Precigen" or the "Company") (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

Oct 28, 2020 10:41 pm ET

PGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Seppen v. Precigen, Inc., f/k/a Intrexon Corporation, et al., (Case No. 3:20-cv-07586) on behalf of persons and entities that purchased or otherwise acq

Oct 28, 2020 07:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Credit Acceptance Corporation, Precigen, Royal Caribbean, and Mesoblast and Encourages Investors to Con

Oct 28, 2020 06:20 pm ET

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Precigen, Inc. f/k/a Intrexon Corporation of Class Action Lawsuit and Upcoming Deadline – PGEN

Oct 26, 2020 05:35 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, Securities Fraud Action Filed, Application Deadlin

Oct 26, 2020 05:03 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action against Precigen, Inc. f/k/a Intrexon Corporation Certain Officers - PGEN

NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Precigen, Inc. f/k/a Intrexon Corporation ("Precigen" or the "Company") (NASDAQ: PGEN). The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-07442, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired the Company's securities between May 10, 2017 and March 2, 2020, both dates inclusive (the "Class Period"). Plaintiff seeks to recover

Oct 26, 2020 04:45 pm ET

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact

Oct 26, 2020 12:30 pm ET

DEADLINE REMINDER: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

BENSALEM, Pa., Oct. 26, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Precigen, Inc. ("Precigen" or the "Company") f/k/a Intrexon Corporation ("Intrexon") (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period").

Oct 23, 2020 12:00 pm ET

DEADLINE ALERT for ACB and PGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Oct 23, 2020 11:19 am ET

PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

Oct 21, 2020 07:26 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Precigen, Inc (f/k/a Intrexon Corporation) - PGEN

Pomerantz LLP is investigating claims on behalf of investors of Precigen, Inc (f/k/a Intrexon Corporation) (“Precigen” or the “Company”) (NASDAQ: PGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or...

Oct 21, 2020 07:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Aurora Cannabis, Credit Acceptance Corporation, Precigen, and Royal Caribbean and Encourages Investors to Conta

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Aurora Cannabis, Inc. (NYSE: ACB), Credit Acceptance Corporation (NASDAQ: CACC),...

Oct 21, 2020 06:21 pm ET

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Deadline in Securities Class Action First Filed by the Firm; Encourages Investo

Oct 21, 2020 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

LOS ANGELES, Oct. 21, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming December 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Precigen, Inc. ("Precigen" or the "Company") f/k/a Intrexon Corporation ("Intrexon") (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period").

Oct 20, 2020 04:00 pm ET

PRECIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the North

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of persons and entities that purchased or otherwise acquired Precigen, Inc. ("Precigen" or the "Company") f/k/a Intrexon Corporation ("Intrexon") (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period").

Oct 20, 2020 09:13 am ET

Moore Kuehn, PLLC Encourages Investors of PGEN or TCMD to Contact Law Firm

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:

Oct 20, 2020 07:30 am ET

Precigen Strengthens Focus on Strategic Partnerships and Names Gaurav Vij Head of Business Development

GERMANTOWN, Md., Oct. 20, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today named Gaurav Vij as the Company's head of business development. Mr. Vij will have responsibility for accelerating strategic business development activities across Precigen's platform and pipeline programs, including identifying and building new strategic partnerships to rapidly progress core assets. Mr. Vij will report to Precigen's President and CEO, Helen Sabzevari, PhD, and wi

Oct 19, 2020 07:15 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates PGEN, TCMD Investors, Encourages Investors with Losses to Contact Firm, Reminds of Critical Upcoming Deadlines

Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. PGEN Investors Click Here....

Oct 17, 2020 04:22 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Precigen, Inc (f/k/a Intrexon Corporation) - PGEN

Oct 16, 2020 04:32 pm ET

PGEN CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

Oct 16, 2020 11:00 am ET

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON) Investors

LOS ANGELES, Oct. 16, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Precigen, Inc. ("Precigen" or the "Company") f/k/a Intrexon Corporation ("Intrexon") (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"). Precigen investors have until December 4, 2020 to file a lead plaintiff motion.

Oct 15, 2020 06:22 pm ET

PGEN INVESTOR DEADLINE: Bernstein Liebhard Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Precigen Inc., f/k/a Intrexon Corporation

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors that purchased or acquired the securities of Precigen Inc. ("Precigen" or the "Company") (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

Oct 15, 2020 04:56 pm ET

PRECIGEN, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern Distri

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of persons and entities that purchased or...

Oct 15, 2020 12:17 pm ET

ROSEN, A LEADING AND LONGSTANDING FIRM, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Deadline in Securities Class Action First Filed by the Firm – PGEN, XON

Oct 15, 2020 11:00 am ET

PGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Precigen, Inc. f/k/a Intrexon Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 4, 2020

Oct 15, 2020 07:30 am ET

Precigen's UltraPorator™ Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials

GERMANTOWN, Md., Oct. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced US Food and Drug Administration (FDA) clearance and successful technology transfer for its UltraPorator™ system, an exclusive device and proprietary software solution for the scale-up of rapid and cost-effective manufacturing of UltraCAR-T® therapies. The FDA cleared UltraPorator as a manufacturing device for clinical trials of Precigen's investigational UltraCAR-T ther

Oct 14, 2020 08:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, and Mesoblast and Encourages Investors to Contact the Firm

Oct 14, 2020 11:30 am ET

DEADLINE REMINDER: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

Law Offices of Howard G. Smith reminds investors of the upcoming December 4, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Precigen, Inc. (“Precigen” or the “Company”) f/k/a Intrexon Corporation (“Intrexon”) (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25,

Oct 13, 2020 10:00 am ET

PGEN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Precigen, Inc. f/k/a Intrexon Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 4, 2020

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Precigen, Inc. f/k/a Intrexon Corporation ("Precigen" or the "Company") (NASDAQ: PGEN) (NASDAQ: XON) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Precigen securities between May 10, 2017 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/pgen.

Oct 12, 2020 05:53 pm ET

CACC, PGEN INVESTOR FRAUD ALERT: Hagens Berman, National Trial Attorneys, Updates CACC, PGEN Investors on Securities Class Actions, Encourages Investors with Losses to Contact Firm

Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the cases can be found at the links provided. CACC Investors Click Here....

Oct 12, 2020 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON)

Oct 12, 2020 10:00 am ET

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Precigen, Inc. (“Precigen” or “the Company”) (NASDAQ:

Oct 09, 2020 02:18 pm ET

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Precigen, Inc. (“Precigen” or “the Company”) (NASDAQ:

Oct 08, 2020 08:00 pm ET

Portnoy Law: Lawsuit Filed On Behalf of Precigen, Inc. Investors

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Precigen, Inc. f/k/a/ Intrexon Corporation ("Intrexon" or "the Company") (NASDAQ: PGEN, XON) investors that acquired securities between May 10, 2017 and...

Oct 08, 2020 09:00 am ET

Lt. General (Ret.) Thomas Bostick Appointed to CSX Corp. Board of Directors

CSX Corp. (NASDAQ: CSX) today announced that Lt. General (Ret.) Thomas Bostick has been appointed to the company's board of directors, effective immediately. "We are honored to have Tom join the CSX board of directors,” said John Zillmer, chairman...

Oct 07, 2020 06:35 pm ET

PGEN INVESTOR ALERT: Bernstein Liebhard Announces that a Securities Class Action Lawsuit Has Been Filed Against Precigen Inc., f/k/a Intrexon Corporation

Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired the securities of Precigen Inc. ("Precigen" or the "Company") (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

Oct 07, 2020 06:19 pm ET

PGEN INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, Securities Fraud Action Filed

Oct 07, 2020 02:30 pm ET

PRECIGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Precigen, Inc. f/k/a Intrexon Corporation and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased...

Oct 07, 2020 10:07 am ET

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Precigen, Inc. f/k/a Intrexon Corporation (PGEN; XON)

Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Precigen, Inc. f/k/a Intrexon Corporation (“Precigen” or the “Company”) (NASDAQ: PGEN; XON) in the United States District Court for the Northern District of...

Oct 06, 2020 08:15 pm ET

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Deadline in Securities Class Action First Filed by the Firm – PGEN, XON

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the “Class Period”), of the important December 4, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors under the federal securities laws.

Oct 06, 2020 07:00 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON) Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Precigen, Inc. (“Precigen” or the “Company”) f/k/a Intrexon Corporation (“Intrexon”) (NASDAQ: PGEN, XON) securities between May 10, 2017 and September 25, 2020, inclusive (the “Class Period”). Precigen investors hav

Oct 06, 2020 06:04 pm ET

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON) Investors

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Precigen, Inc. (“Precigen” or the “Company”) f/k/a Intrexon Corporation (“Intrexon”) (NASDAQ:

Oct 06, 2020 03:22 pm ET

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON) Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Precigen, Inc. (“Precigen” or the “Company”) f/k/a Intrexon Corporation (“Intrexon”) (NASDAQ:

Oct 06, 2020 09:47 am ET

PGEN LOSSES ALERT: Bernstein Liebhard is Investigating Precigen Inc., f/k/a Intrexon Corporation For Violations of the Securities Laws

Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Precigen Inc. (“Precigen” or the “Company”) (NASDAQ: PGEN, XON) resulting from allegations that Precigen might have issued misleading information to the investing public.

Oct 05, 2020 11:00 pm ET

ROSEN, A TOP RANKED LAW FIRM, First Files Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation – PGEN, XON

Oct 05, 2020 08:00 pm ET

PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Precigen, Inc. (NASDAQ: PGEN) f/k/a Intrexon Corporation on behalf of long-term stockholders. Our investigation concerns...

Oct 05, 2020 07:50 pm ET

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Precigen, Inc. f/k/a Intrexon Corporation – PGEN, XON

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) between May 10, 2017 and September 25, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Precigen f/k/a Intrexon investors under the federal securities laws.

Oct 05, 2020 06:34 pm ET

The Law Offices of Frank R. Cruz Continues Its Investigation of Precigen, Inc. (PGEN) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Precigen, Inc. ("Precigen" or the "Company") (NASDAQ:

Oct 05, 2020 05:49 pm ET

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Precigen, Inc. (PGEN), f/k/a Intrexon Corp. (XON) Investors with Losses to Contact Its Attorneys, SEC Finds Company Violated Securities Laws

Hagens Berman urges Precigen, Inc. (NASDAQ: PGEN) (f/k/a Intrexon) investors with significant losses to submit your losses now. Relevant Period: Before Sept. 25, 2020Visit: www.hbsslaw.com/investor-fraud/PGENContact An Attorney Now:...

Oct 05, 2020 12:58 pm ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Precigen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Precigen, Inc. (“Precigen” or “the Company”) (NASDAQ:

Oct 05, 2020 09:47 am ET

PGEN INVESTIGATION ALERT: Bernstein Liebhard Is Investigating Precigen Inc., f/k/a Intrexon Corporation for Violations of the Securities Laws

Oct 02, 2020 06:00 pm ET

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Precigen, Inc. f/k/a Intrexon Corporation (“Intrexon” or the “Company”) (NASDAQ: PGEN, XON) investors concerning the Company’s possible violations of federal securities laws.

Oct 02, 2020 05:02 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Precigen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Precigen, Inc. (“Precigen” or “the Company”) (NASDAQ:

Oct 02, 2020 04:30 pm ET

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Precigen, Inc. f/k/a Intrexon Corporation (PGEN, XON) on Behalf of Investors

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Precigen, Inc. f/k/a Intrexon Corporation (“Intrexon” or the “Company”) (NASDAQ:

Oct 02, 2020 03:20 pm ET

The Law Offices of Frank R. Cruz Announces Investigation of Precigen, Inc. (PGEN) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Precigen, Inc. ("Precigen" or the "Company") (NASDAQ:

Oct 02, 2020 12:44 pm ET

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Precigen, Inc. f/k/a Intrexon Corporation – PGEN, XON

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Precigen, Inc. f/k/a Intrexon Corporation (NASDAQ: PGEN, XON) resulting from allegations that the Company may have issued materially misleading business information to the investing public.

Aug 06, 2020 07:30 am ET

Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure

GERMANTOWN, Md., Aug. 6, 2020 /PRNewswire/ -- Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627), a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure. The INXN-4001 investigational therapy uses a non-viral plasmid designed to constitutively express human SDF-1α, VEGF165, and S100A1 gene products, which affect progenitor cell recruitment, a

Aug 03, 2020 07:30 am ET

Precigen to Announce Second Quarter and First Half 2020 Financial Results on August 10th

GERMANTOWN, Md., Aug. 3, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release second quarter and first half 2020 financial results after the market closes on Monday, August 10th, 2020. The Company will host a conference call that day at 4:30 pm ET to discuss the results and provide a general business update.

Jun 22, 2020 08:45 am ET

Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T

GERMANTOWN, Md., June 22, 2020 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced preclinical data for its innovative investigational PRGN-3005 UltraCAR-T® in patients with advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer has been published as an e-poster and accompanying audio presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II. The e-poster presentation titled PRGN-3005 UltraCAR-

Jun 11, 2020 07:30 am ET

Precigen to Participate in Upcoming JMP Securities Hematology and Oncology Forum

GERMANTOWN, Md., June 11, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Forum on June 18, 2020, at 1:40 PM ET. Participants may access the live webcast of the event through Precigen's website in the Press & Events section at https://investors.precigen.com/press-and-events.

Jun 04, 2020 04:05 pm ET

Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of Shareholders

GERMANTOWN, Md., June 4, 2020 /PRNewswire/ -- In light of the ongoing COVID-19 pandemic and taking into account guidance and protocols issued by public health and government authorities, Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting to be held on June 19, 2020, at 9:00 a.m., Eastern Time.

Jun 03, 2020 09:31 am ET

Thinking about trading options or stock in Anheuser Busch, Zoom Video Communications, Delta Air Lines, Precigen Inc, or American Airlines?

NEW YORK, June 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BUD, ZM, DAL, PGEN, and AAL.

May 15, 2020 07:30 am ET

Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™ at the AACR Virtual Annual Meeting II in June 2020

GERMANTOWN, Md., May 15, 2020 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced preclinical data for its innovative investigational PRGN-3005 UltraCAR-T™ in patients with advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer will be presented as an e-poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, to be held from June 22-24, 2020. The e-poster presentation titled PRGN-3005 UltraCAR-T: M

May 06, 2020 04:05 pm ET

Precigen Reports First Quarter 2020 Financial Results

GERMANTOWN, Md., May 6, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter financial results for 2020.

Apr 29, 2020 07:30 am ET

Precigen to Announce First Quarter 2020 Financial Results on May 6th

GERMANTOWN, Md., April 29, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release first quarter 2020 financial results after the market closes on Wednesday, May 6th, 2020. The Company will host a conference call that day at 4:15 pm ET to discuss the results and provide a general business update.

Apr 20, 2020 07:36 am ET

Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors

GERMANTOWN, Md., April 20, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I/II trial for Precigen's PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse™ platform designed to activate the immune system to recognize and target HPV+ solid tumors. HPV+ cancers represent

You are here

Precigen Inc (OQ:PGEN)

Business Focus: Pharmaceuticals